determined the number of bottles of isoflurane, sevoflurane and desflurane used for the financial years 1997 to 2007 (July 1 to June 30). Using the institutional pharmacy acquisition cost (in Australian dollars) per bottle, we calculated the monthly inhalational agent cost by multiplying the number of bottles of agent used each year by the acquisition cost per bottle. In order to correct for annual inflation over this time period, the annual volatile agent acquisition cost was adjusted based on the Australian Consumer Price Index (CPI) 5 . The CPI is a current social and economic indicator that is constructed to measure changes over time in the general level of prices of consumer goods from one given period to the next.
In addition, we analysed the pharmacoeconomic effects of using fresh gas inflows from 0.5 to 6 l/minute for each inhalational agent 4 . Several formulae which are based on the pharmacokinetic properties of each inhalational agent have been used to calculate the cost per ml of liquid anaesthetic agent during a 60-minute inhalational agent anaesthetic, at 1 minimum alveolar concentration 6, 7 . All formulae are similar. We used the Dion formula 6 to estimate the volume of inhalational agent used in ml: volatile agent consumption (ml)=CFTM/2412D, where C=concentration of volatile agent (%), F=fresh gas flow (l/minute), T=time (minutes), M=molecular weight (g) and D=density (g/ml). The constant 2412 is derived from the molar volume of gas at room temperature 6 . Dion's formula does not take into account the cost of the breathing circuit used, consumption of soda lime at low fresh gas flows where rebreathing may occur, costs of the carrier gases such as oxygen and nitrous oxide, or operating room staff salaries 8, 9 .
RESULTS
The institutional pharmacy acquisition costs in Australian dollars per bottle for the financial years 1997 to 2004 were isoflurane (250 ml) $157, sevoflurane (250 ml) $336 and desflurane (240 ml) $170. Inflation-adjusted acquisition costs for isoflurane decreased from $117,000 in 1997 to $22,000 in Fresh gas flow analysis demonstrated the pharmacoeconomic advantage of reducing fresh gas flow ( Table 1) . For a given agent, the cost was linearly related to the gas flow: 2 l/minute was four times the cost of 0.5 l/minute. Further, at a given flow rate the cost of sevoflurane was 4.7 times that of isoflurane and the cost of desflurane was 8.6 times that of isoflurane.
DISCUSSION
We used pharmacoeconomic analysis to assess the cost of volatile inhalational agents in a large Australian hospital from 1997 to 2007. Consistent with our hypothesis, we found that sevoflurane and desflurane use and costs markedly increased while isoflurane use and costs decreased. Further, we found that low-flow anaesthesia, particularly with isoflurane, can reduce costs.
Over the 11-year period, total acquisition costs for isoflurane, sevoflurane and desflurane increased 168%, from $132,000 in 1997 to $326,000 in 2007 (inflation-adjusted). This was almost 15 times greater than the 11% increase in patient workload for the same time period. Further, the increase in volatile costs was four times the 43% increase in our total pharmacy anaesthetic budget, from $1,085,000 in 1997 (inflation-adjusted) to $1,550,000 in 2007. Inhalational agents therefore accounted for 12% of the total pharmacy theatre costs in 1997, increasing noticeably to 21% of total costs by 2007. Our findings of increased sevoflurane and desflurane use are consistent with a recent audit from New Zealand 10 . We think this change in use pattern was partly due to anaesthetists' beliefs about perceived favourable pharmacologic advantages, particularly shorter wake-up times 11, 12 . The newer inhalational agents desflurane and sevoflurane have significantly lower blood/gas partition coefficients compared to isoflurane (0.45 and 0.65 vs 1.4, respectively). Theoretically, these less soluble agents are more suitable for use with low fresh gas flows because their poor solubility permits better control of the delivered concentration. The lower solubilities of sevoflurane and desflurane in both blood and tissues confer a more rapid increase and decrease in alveolar concentration during induction of and recovery from anaesthesia compared with that found with the more soluble agent isoflurane. These lower solubilities produce a more rapid awakening and recovery from anaesthesia 13 . However, this theoretical advantage has not translated into clear differences in clinical outcomes in published data 14, 15 as speed of recovery may also be influenced by other factors, such the age of the patient and co-administered depressant drugs. Importantly, many studies evaluating recovery profiles of the inhalational agents were conducted before the use of depth of anaesthesia monitors became more widespread, which may also influence clinically important differences in wake-up times 16 .
As predicted from its lower solubility, immediate awakening after sevoflurane is more rapid than after isoflurane in some [17] [18] [19] [20] [21] but not all [22] [23] [24] [25] studies. Further, in those studies where wake-up times differed, the average difference was only a few minutes 14 . Unless these differences in wake-up times translate into improvements in patient comfort or an increased turnover of cases, the clinical importance of such differences remains doubtful 14, 15 . Although there are limited studies available comparing desflurane with isoflurane, most reports [26] [27] [28] [29] [30] , but not all [31] [32] [33] , also demonstrate a more rapid recovery and a shorter time to discharge from the post-anaesthesia recovery unit with desflurane, particularly in procedures of longer duration 26 . Again, for shorter procedures it is unclear whether the differences are clinically important 14 . Therefore, if wake-up time is important, there is some evidence for using desflurane rather than isoflurane for longer procedures, but little, if any, evidence to support using sevoflurane or desflurane in preference to isoflurane for short procedures. Changing from isoflurane to desflurane towards the end of the case is not associated with faster operating room exit times in the outpatient setting 34 , although similar studies have not been conducted in patients undergoing longer procedures.
Studies comparing rapidity of awakening from desflurane versus sevoflurane report more conflicting results. Many studies suggest no differences in recovery profiles 22, 32, 35, 36 , but others report a more rapid awakening with desflurane 29, [37] [38] [39] [40] [41] [42] . It may be argued that for patients undergoing longer procedures, in order to balance the cost of using desflurane or sevoflurane with their pharmacokinetic benefits of quicker recovery times, the cheaper isoflurane should be used for maintenance of anaesthesia, changing to desflurane or sevoflurane towards the end. At present, however, there are no studies to support or refute this proposal.
Factors that influence cost of the inhalational agents include agent acquisition costs (determined by the manufacturer and largely beyond the control of the anaesthetist), potency of the inhalational agent (the more potent the drug, the less is required to achieve the same clinical effect), duration of surgery (the longer the operation, the more agent required) and the volume of vapour produced from each ml of anaesthetic agent, which is inherent in the specific pharmacokinetic properties of the agent and again beyond the control of the anaesthetist 3, 7 . Another important determinant of inhalational agent cost, however, is fresh gas flow rates. Actual fresh gas flow rates used were not recorded as part of this study. At our institution, there is no anaesthetic protocol for using low fresh gas flow rates. Accordingly, fresh gas flow rates for all three inhalational agents studied vary from 0.5 l/minute to greater than 6 l/minute. Although fresh gas flow rates were not recorded, it is recognised that lower flow rates decrease volatile agent consumption and costs 3, 7, 43 . McKenzie effectively demonstrated significant savings of over $100,000 (inflationadjusted) over a 20-month period, which was achieved by "reinforcing" a low-flow anaesthesia policy 43 . While minimal fresh gas flows (0.5 l/minute) are possible with any agent, in Australia the manufacturer's minimum recommended flow rate for sevoflurane is 2 l/min for "prolonged procedures" 7, 44 . This recommendation is due to theoretical concerns about renal toxicity that have not been borne out in clinical studies 45, 46 . The manufacturer's recommendation is likely to affect the fresh gas flow rates Australian anaesthetists use for sevoflurane, a proposition supported by an audit in our department (unpublished results). The recent audit at one New Zealand hospital, however, found that while anaesthetists used sevoflurane in about 90% of cases, mean flow rates were 1.3 l/minute 10 .
Our study has several limitations. First, it is a single centre study and this limits the external validity of our findings. Our hospital however, is a large city teaching hospital with most of the surgical specialties 47 . In addition, we have over 40 consultant anaesthetists, many of whom work in other hospitals, and over 20 trainees each year, all of whom work in other hospitals. Second, like others 10 , we do not have data on other aspects of anaesthetic practice such as adjuvant infusions and costs and choice of carrier gas or gases such as oxygen and nitrous oxide. Finally, Dion's formula utilises fixed constants for the known volatile agents and does not take temperature and atmospheric pressure into consideration in the calculation. The main strength of our study is that the data were collected over an 11-year period and it demonstrates a progressive, unequivocal increase in sevoflurane and desflurane use, despite the number of annual cases remaining relatively constant. Our study reinforces the relatively straightforward way that Dion's formula can be used to calculate costs of inhalational agents. This method is a simple pharmacoeconomic tool that can be used by every anaesthetist.
In conclusion, we found an important trend toward the use of the more expensive inhalational anaesthetic agents sevoflurane and desflurane rather than the cheaper isoflurane over an 11-year period. Acquisition costs for inhalational agents are only one of the elements in a larger complex model that determines the total cost of surgery 2, 18 . Strategies to control rising costs include cheaper drug acquisition costs, evidence-based use of agents and minimising drug wastage by using low fresh gas inflow anaesthesia 3 . We think use of the more expensive anaesthetic agents sevoflurane and desflurane is justified only if there is clear evidence to support improvements in either patient outcome, such as less nausea and vomiting, or cost-efficiency, such as savings on the overall cost of anaesthesia achieved through increased surgical caseload, reduced length of stay in the post-anaesthesia care unit or salary savings from reduced staff overtime 2, 48 . At present, the evidence, based on wake-up times, appears not to support using desflurane or sevoflurane rather than isoflurane during many procedures. Our hospital delivers more than 27,000 minimum alveolar concentration hours of anaesthesia per year. Our pharmacoeconomic modelling suggests for every 10,000 minimum alveolar concentration hours of anaesthesia, if isoflurane with fresh gas inflow of 0.5 l/minute replaced sevoflurane with fresh gas inflow of 2 l/minute, we may save up to $250,000 or about half this amount if gas flows were 1.3 l/minute 10 . This kind of saving would be about 15% of our hospital's total annual operational pharmacy budget for theatre (personal communication, K. garrett, Director of Austin Pharmacy) and should be easy to achieve. In addition to these financial savings, this lower fresh gas flow may have environmental benefits 49 . While we recognise that much larger cost savings can be achieved by system-wide improvements in efficiency of resource utilisation in the health care setting, evidence-based choice of anaesthetic agent and gas inflow rates is a small part of a larger whole.
